美国药品价格调查引发新关税威胁

Core Viewpoint - The Trump administration is intensifying its attack on U.S. trade partners regarding drug pricing, preparing to launch a new investigation to lay the groundwork for a new round of tariffs [1] Group 1: Investigation and Policy Actions - The upcoming investigation will be based on Section 301 of the Trade Act of 1974, focusing on whether U.S. trade partners have underpaid for drugs [1] - This investigation is part of a broader effort by the Trump administration to lower drug prices for American consumers [1] Group 2: Drug Pricing Disparities - Research from RAND Corporation indicates that average drug prices in the U.S. are nearly three times higher than in many other developed countries [1] - For example, the monthly cost of the popular weight-loss drug Ozempic produced by Novo Nordisk is $936 in the U.S., compared to $147 in Canada and $83 in France [1] Group 3: Industry Reactions - Pfizer and AstraZeneca have recently announced agreements with the Trump administration to lower prices on certain products [1] - Novo Nordisk and Eli Lilly have indicated that they have discussed pricing issues with government officials [1] - The threat of high tariffs on imported brand-name and generic drugs as part of a national security investigation has caused concern within the pharmaceutical industry [1]